Monitoring for Human Papillomavirus Vaccine Impact Among Gay, Bisexual, and Other Men Who Have Sex With Men—United States, 2012–2014

Meites, Elissa; Gorbach, Pamina M.; Gratzer, Beau; Panicker, Gitika; Steinau, Martin; Collins, Tom; Parrish, Adam; Randel, Cody; McGrath, Mark R.; Carrasco, Steven; Moore, James R.; Zaidi, Akbar A.; Braxton, Jim; Kerndt, Peter R.; Unger, Elizabeth R.; Crosby, Richard A.; Markowitz, Lauri E.

doi:10.1093/infdis/jiw232

Cited by 50 publications

(43 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…22 However, a recent study among 922 vaccine-eligible gay, bisexual, and other MSM aged 18–26 years in 2 US cities demonstrated that while 90.9% of HIV-positive young MSM and 62.9% of other MSM were seropositive for any 4vHPV types, only 29.5% of HIV-positive MSM and 8.5% of other MSM were seropositive for all four 4vHPV types of HPV. 23 These findings suggest that sexually active young MSM can benefit from vaccination.…”

Section: Discussionmentioning

confidence: 94%

Increasing Human Papillomavirus Vaccine Coverage Among Men Who Have Sex With Men—National HIV Behavioral Surveillance, United States, 2014

Oliver

Hoots

Paz–Bailey

et al. 2017

JAIDS Journal of Acquired Immune Deficiency Syndromes

Self Cite

View full text Add to dashboard Cite

Background Human papillomavirus (HPV) can cause oropharyngeal and anogenital cancers among men who have sex with men (MSM). In 2011, the Advisory Committee on Immunization Practices (ACIP) extended HPV vaccine recommendations to males through age 21 and MSM through age 26. Because of this distinction, vaccination for some MSM might rely on sexual behavior disclosure to health care providers. Receipt of ≥1 HPV vaccination among MSM aged 18–26 in National HIV Behavioral Surveillance (NHBS) was 4.9% in 2011. We evaluated HPV vaccine coverage and associated factors among MSM in 2014. Setting Twenty US metropolitan statistical areas in 2014. Methods Coverage was calculated as percentage of MSM self-reporting ≥1 HPV vaccination. Adjusted prevalence ratios were calculated from Poisson regression models to estimate associations of demographic and behavioral characteristics with HPV vaccination. Results Among 2892 MSM aged 18–26 years, HPV vaccine coverage was 17.2%. Overall, 2326 (80.4%) reported a health care visit within 12 months, and 2095 (72.4%) disclosed MSM attraction or behavior to a health care provider. Factors associated with vaccination included self-reported HIV infection; having a health care visit within 12 months, health insurance, or a usual place of care; and disclosing MSM attraction or behavior to a health care provider. Conclusions Since the 2011 recommendation for vaccination of males, HPV vaccine coverage among MSM increased, but remains low. Most MSM reported a recent health care visit and disclosed sexual behavior, indicating opportunities for vaccination. Potential strategies for increasing MSM coverage include improving access to recommended care, and offering education for providers and patients.

show abstract

Section: Discussionmentioning

confidence: 94%

Increasing Human Papillomavirus Vaccine Coverage Among Men Who Have Sex With Men—National HIV Behavioral Surveillance, United States, 2014

Oliver

Hoots

Paz–Bailey

et al. 2017

JAIDS Journal of Acquired Immune Deficiency Syndromes

Self Cite

View full text Add to dashboard Cite

show abstract

“…Since 2011, the Advisory Committee on Immunization Practice (ACIP) recommended routine vaccination for all males at ages 11‐12 years, through age 21 years for men not previously fully vaccinated, and through age 26 years for MSM and immunocompromised men, including those with HIV infection . Quadrivalent HPV vaccination of MSM was likely reported as an effective and cost‐effective way for reducing the burden of HPV‐related disease in MSM .…”

Section: Discussionmentioning

confidence: 99%

“…35 Since 2011, the Advisory Committee on Immunization Practice (ACIP) recommended routine vaccination for all males at ages 11-12 years, through age 21 years for men not previously fully vaccinated, and through age 26 years for MSM and immunocompromised men, including those with HIV infection. [36][37][38] Quadrivalent HPV vaccination of MSM was likely reported as an effective and cost-effective way for reducing the burden of HPV-related disease in MSM. 39,40 Particularly Current evidences support to achieve the target of universal vaccination with a gender-neutral approach by considering both HPV vaccination's clinical effectiveness and economic sustainability.…”

Section: Genotype Distribution In Hpv Positive Msmmentioning

confidence: 99%

Prevalence of anal, oral, penile and urethral Human Papillomavirus in HIV infected and HIV uninfected men who have sex with men

Ucciferri

Tamburro

Falasca

et al. 2017

Journal of Medical Virology

View full text Add to dashboard Cite

Aims of the study were to evaluate Human Papillomavirus (HPV) and type-specific prevalence in four anatomical sites in HIV infected men who have sex with men (MSM) compared with HIV uninfected MSM. Participants were recruited among the attendees of Infectious Diseases Clinics in Central Italy. A trained medical practitioner collected by interview sociodemographic data and information on medical history, sexual behavior, and drug use. Swabs from anal canal, oral cavity, urethral mucosa, and coronal sulcus were tested for HPV DNA and genotyping. Ninety MSM were enrolled, 45 subjects within each group. Overall, 48.9% MSM were HPV positive and prevalence was higher in HIV infected men (60.0% vs 37.8%, P = 0.035). HPV at multiple anatomic sites occurred in 59.1% MSM, with 34.1% and 22.7% at two and three sites, respectively. Prevalence of anal, coronal sulcus, oral, and urethral HPV was 96.3%, 37%, 21.6%, and 18.5% in HIV infected MSM, and 70.6%, 70.6%, 29.4%, and 23.5% among HIV uninfected. A similar proportion of HIV infected and uninfected MSM (59.2% and 58.8%) carried at least one high-risk genotype. Prevalence of types covered by nonavalent vaccine was 77.8% in HIV infected compared with 82.3% in HIV uninfected MSM. HPV 58 and 16 were mostly detected in HIV positive (43.7% and 31.2%) and negative MSM (50.0% and 40.0%). HPV detection rate underlined the high vulnerability of MSM to acquire multisite infections, characterized by various genotype combinations. Since nonavalent vaccine could have prevented 80% of HPV infections, study findings support the implementation of vaccination programs among MSM.

show abstract

“…Detailed methods have been reported previously. 30 Enrollment occurred at 3 clinical facilities providing sexually transmitted disease (STD), HIV, and other clinical care to lesbian, gay, bisexual, and transgender (LGBT) populations in 2 US cities: Chicago, IL (n = 328 [32%]) and Los Angeles, CA (n = 705 [68%]) during July 2012 to August 2014. In Chicago, 7.5% (29/384) of those invited and age eligible refused; and in Los Angeles, 4.4% (35/791) of those invited and age eligible refused.…”

Section: Methodsmentioning

confidence: 99%

Human Papillomavirus Vaccination Among Young Men Who Have Sex With Men and Transgender Women in 2 US Cities, 2012–2014

Gorbach¹,

Cook²,

Gratzer³

et al. 2017

Sexual Trans Dis

Self Cite

View full text Add to dashboard Cite

Background Since 2011, in the United States, quadrivalent human papillomavirus (HPV) vaccine has been recommended for boys aged 11 to 12 years, men through age 21, and men who have sex with men (MSM) through age 26. We assessed HPV vaccination coverage and factors associated with vaccination among young MSM (YMSM) and transgender women (TGW) in 2 cities. Methods During 2012–2014, 808 YMSM and TGWaged 18 to 26 years reported vaccination status in a self-administered computerized questionnaire at 3 sexually transmitted disease (STD) clinics in Los Angeles and Chicago. Associations with HPV vaccination were assessed using bivariate and multivariable models to calculate adjusted odds ratios (aORs) and 95% confidence intervals (CIs). Results Few of the diverse participants (Hispanic/Latino, 38.0%; white, 27.0%; and black/African American, 17.9%) reported receiving 1 or more HPV vaccine doses (n = 111 [13.7%]) and even fewer reported 3 doses (n = 37 [4.6%]). A multivariable model found associations between vaccination and having a 4-year college degree or higher (aOR, 2.83; CI, 1.55–5.17) and self-reported STDs (aOR, 1.21; CI, 1.03–1.42). In a model including recommendation variables, the strongest predictor of vaccination was a health care provider recommendation (aOR, 11.85; CI, 6.70–20.98). Conclusions Human papillomavirus vaccination coverage was low among YMSM and TGW in this 2–US city study. Our findings suggest further efforts are needed to reach YMSM seeking care in STD clinics, increase strong recommendations from health care providers, and integrate HPV vaccination with other clinical services such as STD testing.

show abstract

Monitoring for Human Papillomavirus Vaccine Impact Among Gay, Bisexual, and Other Men Who Have Sex With Men—United States, 2012–2014

Cited by 50 publications

References 45 publications

Increasing Human Papillomavirus Vaccine Coverage Among Men Who Have Sex With Men—National HIV Behavioral Surveillance, United States, 2014

Increasing Human Papillomavirus Vaccine Coverage Among Men Who Have Sex With Men—National HIV Behavioral Surveillance, United States, 2014

Prevalence of anal, oral, penile and urethral Human Papillomavirus in HIV infected and HIV uninfected men who have sex with men

Human Papillomavirus Vaccination Among Young Men Who Have Sex With Men and Transgender Women in 2 US Cities, 2012–2014

Contact Info

Product

Resources

About